Shared decision making for hormone therapy (AJP Nov 2019)

Accredited CPD
Group 2

Provider: Australian Journal of Pharmacy
Author: Debbie Rigby

CPD Credits: 2

Overview 

This article describes the treatment options for menopausal hormone therapy (MHT) and looks at the recent evidence about of the risks and benefits of MHT so that pharmacists can make appropriate recommendations for treatment associated with the least risk of breast cancer and thromboembolism.

Learning Objectives

After completing this activity, pharmacists should be able to:

  1. discuss treatment options for hormone therapy;
  2. evaluate recent evidence on the risk/benefit ratio of hormone therapy;
  3. recommend preparations associated with the least risk of breast cancer and thromboembolism.

The 2016 Competency Standards addressed by this activity include: 1.5, 1.6, 2.2, 2.4, 3.1, 3.2, 3.3

Accreditation number:  CX19067   Accreditation expires: 1/11/2021
This activity has been accredited for 1.0 hour of Group One CPD (or 1.0 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan, which may be converted to 1.0 hour of Group Two CPD (or 2.0 CPD credits) upon successful completion of the associated assessment activity.